Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00256698 · OUTCOME

Duration of Clinical Benefit (DoCB)

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy · Source last updated 2012-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

What was measured

Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders

Groups in this outcome

Fulvestrant + Anastrozole

Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg

Anastrozole

Anastrozole 1 mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Fulvestrant + Anastrozole258
Anastrozole256

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Fulvestrant + Anastrozole18.5Not reported1.6446.95Not reported
Anastrozole18.1Not reported5.1954.34Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.64
        upper Limit
        46.95
        value
        18.5
      2. group Id
        OG001
        lower Limit
        5.19
        upper Limit
        54.34
        value
        18.1
denoms
  1. counts
    1. group Id
      OG000
      value
      258
    2. group Id
      OG001
      value
      256
    units
    Participants
description
Median time from randomisation until objective progression or death (in the absence of objective progression), measured only in those patients who are clinical benefit responders
dispersion Type
Full Range
groups
  1. description
    Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg
    id
    OG000
    title
    Fulvestrant + Anastrozole
  2. description
    Anastrozole 1 mg
    id
    OG001
    title
    Anastrozole
param Type
MEDIAN
reporting Status
POSTED
time Frame
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
title
Duration of Clinical Benefit (DoCB)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice